Further information:

• Link to news release on the FDA approval of aducanumab
• Link to FDA prescribing information (for US)
• Link to Budd Haeberlein et al., J Prev Alz Dis., 2022: Results of two randomized Phase 3 studies of Aducanumab
• Link to Salloway et al., JAMA Neurology 2021
• Link to news release - Neurimmune to regain global rights to aducanumab